# Study to Evaluate the Effect of Naltrexone and Bupropion Extended-Release Combination on Cardiac Repolarization in Healthy Participants

> **NCT02735603** · PHASE1 · COMPLETED · sponsor: **Orexigen Therapeutics, Inc** · enrollment: 84 (actual)

## Conditions studied

- Heart Repolarization

## Interventions

- **DRUG:** Naltrexone HCl/bupropion HCl
- **OTHER:** Placebo
- **DRUG:** Moxifloxacin

## Key facts

- **NCT ID:** NCT02735603
- **Lead sponsor:** Orexigen Therapeutics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04
- **Primary completion:** 2016-07
- **Final completion:** 2016-10
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2016-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02735603

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02735603, "Study to Evaluate the Effect of Naltrexone and Bupropion Extended-Release Combination on Cardiac Repolarization in Healthy Participants". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02735603. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*